![Robert Waltermire](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 3 M $ in data 31/07/2026
Robert Waltermire is currently the Chief Pharmaceutical Development Officer at Madrigal Pharmaceuticals, Inc. He previously worked at Venatorx Pharmaceuticals, Inc. as the Senior Vice President-CMC from 1988 to 2020.
Waltermire completed his undergraduate degree at Franklin & Marshall College in 1984 and obtained his doctorate from the University of Maryland in 1988.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 05/03/2025 | 5.789 ( 0,03% ) | 3 M $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02/08/2021 |
| Società | Posizione | Fine |
|---|---|---|
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel anti-infectives to treat multi-drug-resistant bacterial and viral infections | Corporate Officer/Principal | 01/01/2020 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel anti-infectives to treat multi-drug-resistant bacterial and viral infections | Health Technology |
Franklin & Marshall College
 Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Maryland
 University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Madrigal Pharmaceuticals, Inc.
 Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
